Eisai's farletuzumab misses in ovarian cancer

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving progression-free survival (PFS) vs. placebo plus carboplatin and taxane chemotherapy in the Phase III FAR 131 trial to treat platinum-sensitive epithelial ovarian cancer in first relapse. The double-blind, international trial enrolled 1,100 patients. Eisai, which said a post hoc exploratory analysis showed a trend toward improved PFS in undisclosed patient subgroups, said it will determine a new development strategy for farletuzumab based on discussion with external experts and health authorities. ...